FDA provides Study May Proceed letter for open-label, randomized phase 3 protocol in soft tissue sarcoma, and plans to initiate phase 3 study in first half of 2024
SHELTON, Conn., Jan. 3, 2024.
A full dose of lurbinectedin plus a low dose of doxorubicin was clinically active and tolerable in patients with advanced or metastatic soft tissue sarcomas, supporting its continued investigation in those with leiomyosarcoma.
Susan H. Markwica died peacefully on Feb. 8, 2023, surrounded by her family. She was 70. Susan was a loving mom, partner, and friend. Susan was born and raised in Glastonbury, Conn. She earned her undergraduate degree in peace and conflict studies from Earlham College, and her graduate degree in counseling psychology from Antioch University. […]
Susan H. Markwica, 70, died peacefully on Wednesday morning, Feb. 8, 2023. She was recently predeceased by her partner, Frank M. Markwica, in December 2022. She is survived by her daughter, Anna Markwica Owen, and son-in-law, Dominic Owen. Her funeral service will be held at a later date, and a complete obituary will appear in […]